Our study on cellular magnesium imbalance in liver disease is now in press (doi:10.1016/j.jhep.2021.01.043) in the Journal of Hepatology!

Patients with liver disease were found to have significantly elevated expression of Cyclin M4 (CNNM4), a protein that modulates cellular magnesium levels. The protein presents a potential therapeutic target for non-alcoholic steatohepatitis, a form of fatty liver disease characterized by inflammation and liver fibrosis. Non-alcoholic fatty liver disease affects billions of people worldwide and is associated with obesity and other comorbidities. The study underscores the importance of magnesium balance for supporting liver health and provides insight into how this essential metal affects lipid metabolism at the cellular level.

The research was conducted by an international team of scientists from the Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), CIBEREHD, University of the Basque Country, NYU, Silence Therapeutics, CABIMER, Universidad Pablo de Olavide, CIBERDEM, Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III, and University Hospital Marqués de Valdecilla/IDIVAL.

Congratulations to lab alumni Dr. Jessica Gruskos and Kevan Chu!

Check out the Highlight in NYU research news